mail
editor@ajptr.com
whatsapp
9409046853
logo

American Journal of PharmTech Research

Published

Avanafil: A Novel Agent for Management of Erectile Dysfunction, Its Clinical And Analytical Approach

Published in June 2013 Issue 3 (Vol. 3, Issue 3, 2013)

Avanafil: A Novel Agent for Management of Erectile Dysfunction, Its Clinical And Analytical Approach - Issue cover

Abstract

Erectile dysfunction is the sexual dysfunction characterized by inability to maintain an erection of penis during sexual performance. Oral phosphodiesterase type 5 inhibitors drugs are successful for treatment of impotence such as sildenafil, vardenafil, tadalafil, alprostadil and avanafil. Clinical trials reveals that avanafil have faster onset of action as well as higher specificity for phosphodiesterase type 5 inhibitors with fewer side effects in comparision of other oral phosphodiesterase type 5 inhibitors drugs. In case of analytical method only LC-MS/MS method has been done. There may be chances of analytical study of avanafil will be done in future by using various spectroscopy method.

Authors (3)

Jasmin Kubawat

Institute of Research and Deve...

View all publications →

YK. Agrawal

Institute of Research and Deve...

View all publications →

Unnati S. Patel

Institute of Research and Deve...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 0.0 MB
Format: PDF

Article Information

Article ID:
AJPTR33008
Paper ID:
AJPTR-01-000495
Published Date:
2013-06-01

Article Impact

Views:4,904
Downloads:2,399

How to Cite

Kubawat & Agrawal & S., U. (2013). Avanafil: A Novel Agent for Management of Erectile Dysfunction, Its Clinical And Analytical Approach. American Journal of PharmTech Research, 3(3), xx-xx. https://ajptr.scholarjms.com/articles/688

Article Actions

Whatsapp